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Abstract
Background:  Therapeutic use and effective function of recombinant urokinase (r-UK) for
occluded ports need the presence of plasminogen.
Methods:  As a therapeutic proof of principle, we demonstrate that the use of r-UK and
autologous plasma effectively reestablishes the function of occluded central venous ports (CVP)
resistant to routine management of catheter occlusion. Five patients with occluded ports resistant
to the routine management were treated.
Results:  All patients were successfully treated with thrombolytic therapy using intraluminal
instillation of r-UK and autologous plasma.
Conclusion:  Instillation of r-UK and autologous plasma is a safe and effective method for
management of CVP occlusion.
Background
Regular application of plasma products or chemotherapy
is often complicated by catheter-related problems such as
blockage. Especially in children, an effective and simple
reestablishment of catheter patency is important. Mainte-
nance of catheter function is usually achieved with flush-
ing (sodium chloride and/or heparin) or urokinase
instillation [1,2]. In the majority of cases low-dose uroki-
nase therapy is a safe and efficacious treatment for cathe-
ter occlusion, frequently obviating the need for catheter
removal. However, in some cases of occluded central
venous ports (CVP), r-UK instillation is not effective.
Because effective therapeutic function of r-UK requires the
presence of plasminogen (see Figure 1) contained in
human plasma, we combined autologous plasma and r-
UK for treatment of occluded CVP in adult and paediatric
patients.
Methods
Five patients with occluded CVP were treated. Patient
characteristics are given in Table 1. After up to eight
attempts every 15 minutes with drawing and pressing to
remove the CVP occlusion with sodium chloride and/or
heparin and subsequently with 10 mg recombinant tissue
plasminogen activator (r-tPA) and 5.000 IU r-UK, we used
a combination of 2 ml of the patient's plasma and 10.000
IU r-UK (Medac GmbH, Germany) dissolved in 1 ml
sodium chloride. The plasma was obtained by centrifuga-
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tion at 1100 g for 10 minutes in a sterile syringe. Next, the
combination of autologous plasma and r-UK were slowly
mixed for 2 minutes within a 5 ml- syringe before applica-
tion. The combination was slowly instilled, whereby a
volume slightly above the CVP volume was injected.
Thirty minutes after instillation, success was assessed by
attempting to aspirate the combination and residual clot
with an empty, sterile syringe. Up to three further attempts
of aspiration were made. If the aspiration was successful,
the catheter lumen was immediately flushed with 10 ml
sodium chloride and/or heparin. Informed consent was
obtained from patients, and, if necessary, from parents, as
approved by the Institutional Ethical Committee.
Results
We report on five patients with an CVP occlusion that
could not be managed by routine procedures. All patients
had internal jugular CVPs, which had all been implanted
in a surgical unit. The indications for CVP placement were
regular infusion of plasma products, chemotherapy and
antibiotics. We tested the new method described in this
paper as a last resort before catheter replacement. All
instillations resulted in successful reestablishment of cath-
eter function after approximately 60 minutes of uroki-
nase/plasma instillation. No patient experienced adverse
effects during or after instillation. No bleeding complica-
tions occurred. The entire management procedure was
easy to perform and well tolerated. In one case the instil-
lation of urokinase and plasma failed. The explanted CVP
showed that a silicon particle, which had originated dur-
ing puncture, had occluded the CVP.
Fibrinolytic System Figure 1
Fibrinolytic System.
Table 1: Patient characteristics.
Initials Age (years) Diagnosis Therapy
NK 6 Hemophilia Factor VIII
AH 3 Hemophilia Factor VIII
HR 67 Hepatocellular Carcinoma Fluorouracil, Folic Acid
MA 51 Colon Carcinoma Fluorouracil, Folic Acid
BH 53 Mammary Carcinoma Fluorouracil, DoxorubicinPublish with BioMed Central    and   every 
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Discussion
Catheter occlusion is a common complication of long-
term CVP placement. Therapeutic fibrinolytic agents like
r-UK or r-tPA are used successfully to restore function of
occluded CVP [1,2] Generally one or two instillationsof r-
UK are required in the majority of patients. A 98.1% pat-
ency rate is reported when treating catheter occlusions in
paediatric patients with r-UK at a concentration of 5,000
IU/mL [4] However, after repeated applications of plas-
minogen activators, a clot may become deprived of plas-
minogen. This will result in the failure of further attempts.
Conclusion
The method we have described in this paper is useful in
such situations. We were able to avoid catheter replace-
ment in all five patients with thrombotic catheter occlu-
sions that were treated with r-UK and autologous plasma.
This is especially important for children.
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